CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the impact on overall survival (OS) of the
addition of cisplatin to gemcitabine vs gemcitabine alone in patients with advanced NSCLC in
poor clinical condition (PS 2), not previously treated.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute, Naples
Collaborators:
Clinical Trials Promoting Group (APRIC/CTPG) Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente Gruppo Oncologico del Lazio (GOL) Gruppo Oncologico Italia Meridionale Gruppo Oncologico Italiano di Ricerca Clinica(GOIRC) Northwest Oncology Cooperative Group(GONO)